Clinical and Translational Science, Volume 19, Issue 11, November 2026.
Paridhi Gupta +3 more
wiley +1 more source
Visualization of a Bruton's Tyrosine Kinase Inhibitor Using Fluorescence and Raman Microscopy. [PDF]
Merchant AS +3 more
europepmc +1 more source
Durable remission with Bruton's tyrosine kinase inhibitor therapy in a patient with leptomeningeal disease secondary to relapsed mantle cell lymphoma. [PDF]
Yohannan B, Sridhar A, Nguyen N, Rios A.
europepmc +1 more source
Remibrutinib as a Therapeutic Option for Solar Urticaria
Photodermatology, Photoimmunology &Photomedicine, Volume 42, Issue 6, November 2026.
Joshua Mijares +3 more
wiley +1 more source
A Novel Bruton's Tyrosine Kinase Inhibitor Suppresses Pancreatic Neuroendocrine Neoplasms Progression via ATF3-Induced Ferroptosis. [PDF]
Hu P +10 more
europepmc +1 more source
Case Report: Secondary neurolymphomatosis successfully treated with sequential Bruton's tyrosine kinase inhibitor and bispecific antibody therapy. [PDF]
Oura M +11 more
europepmc +1 more source
Covalent Bruton's tyrosine kinase inhibitor HZ-A-018 in patients with relapsed or refractory B cell malignancies: A multicenter phase I study. [PDF]
Wu G +13 more
europepmc +1 more source
Irreversible covalent Bruton's tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trial. [PDF]
Takeuchi T +3 more
europepmc +1 more source
Evobrutinib, a covalent Bruton's tyrosine kinase inhibitor: Mass balance, elimination route, and metabolism in healthy participants. [PDF]
Scheible H +10 more
europepmc +1 more source
Cryptococcal Infection in a Patient With Chronic Lymphocytic Leukaemia Receiving Acalabrutinib, a Bruton's Tyrosine Kinase Inhibitor: A Case Report. [PDF]
Al-Shaker AN +3 more
europepmc +1 more source

